Pacific Biosciences of California: Analyst Sentiment Shifts Amid Revenue Growth and Regulatory Approval

Pacific Biosciences' consensus analyst price target has risen from $2.23 to $2.25, driven by ongoing revenue growth and a lower discount rate. Recent share purchases by ARK Investment, led by Cathie Wood, and regulatory approval in China for the Sequel II CNDx system support the company's growth momentum and long-term prospects. However, limited direct bearish commentary suggests some analysts are waiting for further evidence of sustained revenue growth or execution consistency before adopting a more positive outlook.